| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2009-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_340747f9310b7b147c56544e2f30ed6b |
| publicationDate |
2011-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20110082564-A |
| titleOfInvention |
How to treat or prevent thrombosis using dabigatran etexilate or a salt thereof that has improved efficacy over conventional warfarin therapy |
| abstract |
The present invention relates to a method of preventing stroke in a patient suffering from atrial fibrillation, wherein the patient does not have any risk factors for major bleeding events, and the method comprises 150 mg of dabigatran etexilate, optionally pharmaceutical Administering to said patient in bid in the form of an acceptable salt thereof. |
| priorityDate |
2008-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |